雷帕鸣西罗莫司片的药效是怎么样的好用吗

For patients who receive a kidney transplant, rejection after surgery is what everyone is most worried about. This may mean that the surgical treatment fails and the patient cannot survive long-term. Also known as sirolimus, the approved indication is to treat patients 13 years of age or older who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids.

How effective is Rapamin Sirolimus Tablets?

Rapamin Sirolimus Tablets is a new, powerful, low-toxic macrolide immunosuppressive drug. It is mainly used clinically to prevent rejection of kidney transplants. It does not inhibit calcineurin after binding to cytoplasmic proteins, so it can completely avoid the nephrotoxicity of calcineurin inhibitors (CNI). It is one of the best choices when liver or renal insufficiency occurs after organ transplantation or when CNI cannot reach the ideal drug concentration.

Rapamin combined with low-dose cyclosporine A is a better immunosuppressive treatment option after renal transplantation, and the use of rapamin can reduce the dose of CNI. After renal transplantation, it is safe and effective to control the steady-state trough concentration of rapamycin at 4-8ng/ml or 5-8ng/ml. Rapamin also reduces the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

It can be seen that the use of sirolimus tablets in kidney transplant patients can not only effectively reduce the risk of rejection, but is also relatively safe. However, immunosuppression may also increase the risk of infection, including activation of underlying viral infections (including BK virus-related nephropathy), fatal infections, and sepsis. Patients should be treated prophylactically for Pneumocystis jiroveci pneumonia (PCP) 1 year after transplantation and against cytomegalovirus (CMV) 3 months after transplantation.

Recommended related hot articles: /newsDetail/80098.html